Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ArthroCare/Opus integration ahead of schedule

This article was originally published in The Gray Sheet

Executive Summary

Coblation RF tissue removal tech developer will complete the transition of Opus Medical's manufacturing operations into its Costa Rica facility during the first half of 2005 following the Nov. 15 purchase of the soft tissue orthopedic repair system maker (1"The Gray Sheet" Nov. 22, 2004, In Brief). During the fourth quarter, ArthroCare brought Costa Rica's Opus production on line and completed planned distribution changes for Opus and Coblation product lines. ArthroCare's preliminary Q4 results include revenue of $42.7 mil., up 31.4%...

You may also be interested in...



ArthroCare completes Opus acquisition

Coblation technology developer finalizes $130 mil. purchase of soft tissue orthopedic repair system maker Opus Medical Nov. 15 (1"The Gray Sheet" Sept. 13, 2004, p. 14). ArthroCare expects Opus to generate $16 mil.-$17 mil. in 2004 revenue from AutoCuff anchoring system sales...

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel